CD80 Protein (CD80) (AA 35-242) (Fc Tag)

Catalog No. ABIN2180845

This Recombinant CD80 protein is produced in HEK-293 Cells. There are 3 publications available.

Quick Overview for CD80 Protein (CD80) (AA 35-242) (Fc Tag) (ABIN2180845)

Target: CD80

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purity: >95 % as determined by SDS-PAGE.

Grade: HPLC verified

Product Details

Protein Characteristics: AA 35-242

Purification tag / Conjugate: This CD80 protein is labelled with Fc Tag.

Sequence: AA 35-242

Characteristics: This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 50 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 50 mM Tris, 100 mM Glycine, pH 7.5

Handling Advice: Please avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

References

Ganesan, Moon, Barakat: "Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study." in: Biochimica et biophysica acta. General subjects, Vol. 1862, Issue 12, pp. 2764-2778, (2019) (PubMed).

Ganesan, Ahmed, Okoye, Arutyunova, Babu, Turnbull, Kundu, Shields, Agopsowicz, Xu, Tabana, Srivastava, Zhang, Moon, Belovodskiy, Hena, Kandadai, Hosseini, Hitt, Walker, Smylie, West, Siraki, Lemieux et al.: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." in: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).

Gmyrek, Pingel, Choi, Green: "Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma." in: Cellular immunology, Vol. 319, pp. 28-34, (2017) (PubMed).

Target Details

Target: CD80

Alternative Name: B7-1

Background: B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20 - 100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Molecular Weight: 50.0 kDa

NCBI Accession: NP_005182

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints